Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade

Orhan G. Yigitbasi, Maher N. Younes, Dao Doan, Samar A. Jasser, Bradley A. Schiff, Corazon D. Bucana, Benjamin N. Bekele, Isaiah J. Fidler, Jeffrey N. Myers

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with progressive growth of head and neck cancer. Expression of the vascular endothelial growth factor (VEGF) is associated with angiogenesis and progressive growth of tumor. The tyrosine kinase inhibitor NVP-AEE788 (AEE788) blocks the EGF and VEGF signaling pathways. We examined the effects of AEE788 administered alone, or with paclitaxel (Taxol), on the progression of human head and neck cancer implanted orthotopically into nude mice. Cells of two different human oral cancer lines, JMAR and MDA1986, were injected into the tongues of nude mice. Mice with established tumors were randomized to receive three times per week oral AEE788, once weekly injected paclitaxel, AEE788 plus paclitaxel, or placebo. Oral tumors were resected at necropsy. Kinase activity, cell proliferation, apoptosis, and mean vessel density were determined by immunohistochemical immunofluorescent staining. AEE788 inhibited cell growth, induced apoptosis, and reduced the phosphorylation of EGFR, VEGFR-2, AKT, and mitogen-activated protein kinase in both cell lines. Mice treated with AEE788 and AEE788 plus paclitaxel had decreased microvessel density, decreased proliferative index, and increased apoptosis. Hence, AEE788 inhibited tumor vascularization and growth and prolonged survival. Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. These data recommend the consideration of patients with head and neck cancer for inclusion in clinical trials of AEE788.

Original languageEnglish (US)
Pages (from-to)7977-7984
Number of pages8
JournalCancer Research
Volume64
Issue number21
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Mouth Neoplasms
Receptor Protein-Tyrosine Kinases
Cell- and Tissue-Based Therapy
Endothelial Cells
Paclitaxel
Neoplasms
Head and Neck Neoplasms
Apoptosis
Growth
Epidermal Growth Factor
Nude Mice
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
AEE 788
Phosphorylation
Cell Proliferation
Vascular Endothelial Growth Factor Receptor-2
Microvessels
Mitogen-Activated Protein Kinases
Tongue

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yigitbasi, O. G., Younes, M. N., Doan, D., Jasser, S. A., Schiff, B. A., Bucana, C. D., ... Myers, J. N. (2004). Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Research, 64(21), 7977-7984. https://doi.org/10.1158/0008-5472.CAN-04-1477

Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. / Yigitbasi, Orhan G.; Younes, Maher N.; Doan, Dao; Jasser, Samar A.; Schiff, Bradley A.; Bucana, Corazon D.; Bekele, Benjamin N.; Fidler, Isaiah J.; Myers, Jeffrey N.

In: Cancer Research, Vol. 64, No. 21, 01.11.2004, p. 7977-7984.

Research output: Contribution to journalArticle

Yigitbasi, OG, Younes, MN, Doan, D, Jasser, SA, Schiff, BA, Bucana, CD, Bekele, BN, Fidler, IJ & Myers, JN 2004, 'Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade', Cancer Research, vol. 64, no. 21, pp. 7977-7984. https://doi.org/10.1158/0008-5472.CAN-04-1477
Yigitbasi, Orhan G. ; Younes, Maher N. ; Doan, Dao ; Jasser, Samar A. ; Schiff, Bradley A. ; Bucana, Corazon D. ; Bekele, Benjamin N. ; Fidler, Isaiah J. ; Myers, Jeffrey N. / Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. In: Cancer Research. 2004 ; Vol. 64, No. 21. pp. 7977-7984.
@article{9c826472c7c94fc480c795554a940f2d,
title = "Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade",
abstract = "Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with progressive growth of head and neck cancer. Expression of the vascular endothelial growth factor (VEGF) is associated with angiogenesis and progressive growth of tumor. The tyrosine kinase inhibitor NVP-AEE788 (AEE788) blocks the EGF and VEGF signaling pathways. We examined the effects of AEE788 administered alone, or with paclitaxel (Taxol), on the progression of human head and neck cancer implanted orthotopically into nude mice. Cells of two different human oral cancer lines, JMAR and MDA1986, were injected into the tongues of nude mice. Mice with established tumors were randomized to receive three times per week oral AEE788, once weekly injected paclitaxel, AEE788 plus paclitaxel, or placebo. Oral tumors were resected at necropsy. Kinase activity, cell proliferation, apoptosis, and mean vessel density were determined by immunohistochemical immunofluorescent staining. AEE788 inhibited cell growth, induced apoptosis, and reduced the phosphorylation of EGFR, VEGFR-2, AKT, and mitogen-activated protein kinase in both cell lines. Mice treated with AEE788 and AEE788 plus paclitaxel had decreased microvessel density, decreased proliferative index, and increased apoptosis. Hence, AEE788 inhibited tumor vascularization and growth and prolonged survival. Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. These data recommend the consideration of patients with head and neck cancer for inclusion in clinical trials of AEE788.",
author = "Yigitbasi, {Orhan G.} and Younes, {Maher N.} and Dao Doan and Jasser, {Samar A.} and Schiff, {Bradley A.} and Bucana, {Corazon D.} and Bekele, {Benjamin N.} and Fidler, {Isaiah J.} and Myers, {Jeffrey N.}",
year = "2004",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-04-1477",
language = "English (US)",
volume = "64",
pages = "7977--7984",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade

AU - Yigitbasi, Orhan G.

AU - Younes, Maher N.

AU - Doan, Dao

AU - Jasser, Samar A.

AU - Schiff, Bradley A.

AU - Bucana, Corazon D.

AU - Bekele, Benjamin N.

AU - Fidler, Isaiah J.

AU - Myers, Jeffrey N.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with progressive growth of head and neck cancer. Expression of the vascular endothelial growth factor (VEGF) is associated with angiogenesis and progressive growth of tumor. The tyrosine kinase inhibitor NVP-AEE788 (AEE788) blocks the EGF and VEGF signaling pathways. We examined the effects of AEE788 administered alone, or with paclitaxel (Taxol), on the progression of human head and neck cancer implanted orthotopically into nude mice. Cells of two different human oral cancer lines, JMAR and MDA1986, were injected into the tongues of nude mice. Mice with established tumors were randomized to receive three times per week oral AEE788, once weekly injected paclitaxel, AEE788 plus paclitaxel, or placebo. Oral tumors were resected at necropsy. Kinase activity, cell proliferation, apoptosis, and mean vessel density were determined by immunohistochemical immunofluorescent staining. AEE788 inhibited cell growth, induced apoptosis, and reduced the phosphorylation of EGFR, VEGFR-2, AKT, and mitogen-activated protein kinase in both cell lines. Mice treated with AEE788 and AEE788 plus paclitaxel had decreased microvessel density, decreased proliferative index, and increased apoptosis. Hence, AEE788 inhibited tumor vascularization and growth and prolonged survival. Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. These data recommend the consideration of patients with head and neck cancer for inclusion in clinical trials of AEE788.

AB - Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with progressive growth of head and neck cancer. Expression of the vascular endothelial growth factor (VEGF) is associated with angiogenesis and progressive growth of tumor. The tyrosine kinase inhibitor NVP-AEE788 (AEE788) blocks the EGF and VEGF signaling pathways. We examined the effects of AEE788 administered alone, or with paclitaxel (Taxol), on the progression of human head and neck cancer implanted orthotopically into nude mice. Cells of two different human oral cancer lines, JMAR and MDA1986, were injected into the tongues of nude mice. Mice with established tumors were randomized to receive three times per week oral AEE788, once weekly injected paclitaxel, AEE788 plus paclitaxel, or placebo. Oral tumors were resected at necropsy. Kinase activity, cell proliferation, apoptosis, and mean vessel density were determined by immunohistochemical immunofluorescent staining. AEE788 inhibited cell growth, induced apoptosis, and reduced the phosphorylation of EGFR, VEGFR-2, AKT, and mitogen-activated protein kinase in both cell lines. Mice treated with AEE788 and AEE788 plus paclitaxel had decreased microvessel density, decreased proliferative index, and increased apoptosis. Hence, AEE788 inhibited tumor vascularization and growth and prolonged survival. Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. These data recommend the consideration of patients with head and neck cancer for inclusion in clinical trials of AEE788.

UR - http://www.scopus.com/inward/record.url?scp=7444227578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444227578&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-1477

DO - 10.1158/0008-5472.CAN-04-1477

M3 - Article

C2 - 15520205

AN - SCOPUS:7444227578

VL - 64

SP - 7977

EP - 7984

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -